



HealthHIV.org


Intersectionality
Between
Infectious Disease
and
Drug Use


Handout


Inaugural DC Engage Harm Reduction Conference AUGUST 25, 2022





























HIV Prevention: Pre-Exposure Prophylaxis (Pr	rEP)
 CDC recommends for those having <u>condomless sexual</u> intercourse or sharing injection equipment w/person wir or unknown HIV status, or for those who had recent STI (within 6 months) 	
Inaugural DC Engage Harm Reduction Conference	
AUGUST 25, 2022	ealthHIV >

HIV Prevention: Pre-Exposure Prophylaxis (PrEP) ○ FDA-approved PrEP regimens ○ Oral daily pill (Truvada or Descovy) approved for people at risk through sex or injection drug use. ○ Descovy only approved for men and transgender women (not cis-gender women) ○ Every 2 month injection of cabotegravir (Apretude) approved for people at risk through sex ○ **Taken correctly can be more than 90% effective in preventing in HIV transmission Inaugural DC Engage Harm Reduction Conference AMUSIT 28, 2022 HealthHIV









A Systematic Review and MetaAnalysis of Studies Evaluating the
Effect of Medication Treatment for
Opioid Use Disorder on Infectious
Disease Outcomes

Ratelyn F McNamara, BS, Breanne E Blondi, MPH,
Radi U Hernánder-Ramirez, PBO, Noor Taweh,
Alyssa A Grimshaw, MSLIS, Sandra A Springer, MD ® ®
Open Forum Infectious Diseases, olabzing,
https://doi.org/10.1093/ofid/ofab289
Published: 02 June 2021 Article history ▼

MOUD was associated with:

Greater ART Adherence OR 1.55, 95%CI 1.12-2.10

HIV Viral Suppression OR 2.19, 955 CI 1.88-2.56

